MedTrace Logo

Prevention of Thromboembolic Events in Total Knee Replacement Patients

NCT03393481 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2020-10-08

No results posted yet for this study

Summary

The purpose of the study is to find out whether MAA868, is able to prevent blood clots following your medical condition (surgery for knee replacement)

Conditions

  • Thrombotic Disorders

Interventions

DRUG

MAA868

MAA868 dose 1 and dose 2, single administration, subcutaneous,

DRUG

Enoxaparin

Enoxaparin 40 mg, o.d X 10 days

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-03
Primary Completion
2020-01-08
Completion
2020-04-17

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03393481 on ClinicalTrials.gov